hemoglobin > 10 to ≤ 13 g/dL
1 drugsPredictive biomarker for patient selection in 3 indications
1
Approved Drugs
3
Indications
1
Companies
hemoglobin > 10 to ≤ 13 g/dL is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 3 indications including Anemia, Chronic Kidney Disease, Human Immunodeficiency Virus Infection. Explore the targeted therapies, indications, testing methods, and companies developing hemoglobin > 10 to ≤ 13 g/dL drugs below.
Search hemoglobin > 10 to ≤ 13 g/dL Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting hemoglobin > 10 to ≤ 13 g/dL
| Drug | Company | Therapeutic Area |
|---|---|---|
| RETACRIT | Pfizer | Renal |